DDInter35 DDInter1763
A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Albendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Albendazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Albendazole {u} (Compound) upregulates {v} (Gene) HDAC6
HDAC6 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Albendazole {u} (Compound) downregulates {v} (Gene) KLHL9
KLHL9 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Albendazole {u} (Compound) downregulates {v} (Gene) RFC2
RFC2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Albendazole {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Albendazole {u} (Compound) causes {v} (Side Effect) Urethral disorder
Urethral disorder {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Albendazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Albendazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Albendazole {u} (Compound) upregulates {v} (Gene) HDAC6
HDAC6 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Albendazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Albendazole (Compound) upregulates HDAC6 (Gene) and HDAC6 (Gene) is upregulated by Temsirolimus (Compound)
Albendazole (Compound) downregulates KLHL9 (Gene) and KLHL9 (Gene) is upregulated by Temsirolimus (Compound)
Albendazole (Compound) downregulates RFC2 (Gene) and RFC2 (Gene) is downregulated by Temsirolimus (Compound)
Albendazole (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is downregulated by Temsirolimus (Compound)
Albendazole (Compound) causes Urethral disorder (Side Effect) and Urethral disorder (Side Effect) is caused by Temsirolimus (Compound)
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Albendazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Albendazole (Compound) upregulates HDAC6 (Gene) and HDAC6 (Gene) is upregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)